Fortem Financial Group LLC Takes Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Fortem Financial Group LLC purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 111,183 shares of the company's stock, valued at approximately $772,000.

A number of other large investors have also added to or reduced their stakes in GDRX. Geode Capital Management LLC boosted its stake in shares of GoodRx by 6.3% during the third quarter. Geode Capital Management LLC now owns 982,729 shares of the company's stock valued at $6,823,000 after purchasing an additional 58,610 shares in the last quarter. Barclays PLC raised its holdings in GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company's stock valued at $973,000 after buying an additional 130,219 shares during the last quarter. Pier Capital LLC acquired a new stake in GoodRx during the 3rd quarter worth approximately $3,259,000. EP Wealth Advisors LLC bought a new stake in GoodRx during the 3rd quarter worth approximately $73,000. Finally, Point72 Asset Management L.P. acquired a new position in GoodRx in the 3rd quarter valued at approximately $11,295,000. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Stock Down 1.2 %

GDRX stock traded down $0.06 on Wednesday, reaching $4.86. 769,759 shares of the company traded hands, compared to its average volume of 1,428,082. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a fifty day simple moving average of $5.72 and a 200-day simple moving average of $7.13. GoodRx Holdings, Inc. has a one year low of $4.09 and a one year high of $9.26. The company has a market cap of $1.85 billion, a P/E ratio of -164.00, a price-to-earnings-growth ratio of 3.57 and a beta of 1.29.

Analysts Set New Price Targets

Several research firms have issued reports on GDRX. Barclays lowered their price target on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Monday, November 11th. Citigroup decreased their price target on GoodRx from $10.00 to $7.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Mizuho assumed coverage on GoodRx in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price objective on the stock. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, GoodRx presently has a consensus rating of "Moderate Buy" and an average price target of $8.60.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.